Teva Innovative Medicine & Biosimilar Pipeline

By development stage – as of May 1, 2023


Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of Active Pharmaceutical Ingredients (API), small molecules, novel biologics and biosimilars, our uniquely integrated “One Teva” drug development model combines our strengths in API and generics with our knowledge of innovative drug development. We understand the many ways that health impacts people’s lives, and will continue to invest in new breakthrough treatments while expanding access to high-quality medicines for our patients across the globe.

Technology Platforms:

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Under Regulatory Review

Biosimilar to Humira®
(adalimumab) 01

Biosimilar to Stelara® (Ustekinumab) 01

Digihaler®
(budesonide and formoterol
fumarate dihydrate) 03
(EU)

Pre Submission

Digihaler® 
(beclomethasone dipropionate HFA)
(US)

Phase 3

Biosimilar to Eylea® (aflibercept) 01

Biosimilar to Prolia® & Xgeva® (denosumab)

Biosimilar to Xolair® (omalizumab)

Olanzapine LAI
Schizophrenia

ICS/SABA (TEV-56248)
Asthma

Biosimilar to Simponi® (golimumab) 01

Phase 2

Anti-TL1A (TEV-48574)
Ulcerative Colitis, Crohn’s Disease

Phase 1

TEV-53408
Gastrointestinal

TEV- 56286 02
Multiple System Atrophy

TEV-56192
Neuroscience

Pre-clinical

TEV-46000
Neuroscience

TEV-56278
Oncology

TEV-56279
Neuroscience

TV-48438
Schizophrenia

TEV-56287 02
Parkinson’s Disease

TEV-56285

TEV-54142

TEV-56191

TEV-56261

TEV-56284 01

TEV-56289

TEV-56288
Neuroscience

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Download a PDF version of Teva Innovative Medicine and Biosimilar Pipeline

Download PDF

Teva innovative medicine & biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Pipeline is current as of May 1, 2023.

  1. Back to contents.

    In collaboration with Alvotech for the US market.

  2. Back to contents.

    In collaboration with MODAG.

  3. Back to contents.

    Digital component approved in UK by MHRA